-
Product Insights
Innovations in Individual and Specified Hormones – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Individual and Specified Hormones - Global Pipeline Summary" provides comprehensive information about the Individual and Specified Hormones pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Individual and Specified Hormones report provides key information and data related to: Extensive coverage of the Individual and Specified Hormones under development Review details of major pipeline products which include product description, licensing and collaboration...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Memantine Hydrochloride in Vascular Dementias
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Memantine Hydrochloride in Vascular Dementias report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Memantine Hydrochloride in Vascular Dementias Drug Details: Memantine Hydrochloride (Namenda...
-
Government & Regulation
NewRussia Insurance Industry – Governance, Risk and Compliance
Russia Insurance Industry Regulation Overview The Central Bank of Russia (CBR) acts as the regulator of the Russia insurance industry. The other bodies overseeing the industry are the International Association of Insurance Supervisors (IAIS) and the All-Russian Union of Insurers (BCC). The Russia Insurance Industry governance regulation report provides a detailed analysis of the insurance regulations for life, property, motor, liability, personal accident and health, and marine, aviation, and transit insurance. The report specifies various requirements for establishing and operating...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brentuximab Vedotin in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brentuximab Vedotin in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brentuximab Vedotin in Primary Mediastinal B-Cell Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brentuximab Vedotin in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brentuximab Vedotin in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brentuximab Vedotin in Systemic Sclerosis (Scleroderma) Drug Details: Brentuximab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brentuximab Vedotin in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brentuximab Vedotin in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brentuximab Vedotin in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brentuximab Vedotin in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brentuximab Vedotin in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brentuximab Vedotin in Follicular Lymphoma Drug Details: Brentuximab vedotin (Adcetris)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brentuximab Vedotin in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brentuximab Vedotin in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brentuximab Vedotin in Head And...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glofitamab in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glofitamab in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glofitamab in Non-Hodgkin Lymphoma Drug Details: Glofitamab (Columvi) is a bispecific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glofitamab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glofitamab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glofitamab in Chronic Lymphocytic Leukemia (CLL) Drug Details: Glofitamab...